Post-validation survey for the elimination of blinding trachoma to evaluate the effectiveness of a serological surveillance strategy in two provinces of Morocco
Conduct district-wide field trials of the Pgp3 lateral flow assay to measure the seroprevalence of antibodies against the Chlamydia trachomatis antigen Pgp3 in low-prevalence settings.
Mapping the Potential Risk of Mycetoma Infection in Sudan and South Sudan Using Ecological Niche Modeling
What is the potential distribution of mycetoma in Sudan and South Sudan? What are the most important factors associated with the spatial distriutional patterns of disease cases in Both countries.
What is the distribution of mycetoma in Sudan?
Can behavioural change communication lead to earlier presentation of mycetoma in rural Sudan?
Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Egypt
What is the indicator(s) and accompanying monitoring and evaluation (M&E) strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?
Defining the insecticide resistance status of dengue vectors in Jeddah and Makkah; essential prerequisite to developing an effective response in the event of an outbreak in these important sites.
Cutaneous Leishmaniasis (CL) is exclusively transmitted by the bite of a female sand fly. In collaboration with the Saudi Arabian Ministry of Health, we have developed a programme aiming to prevent and control CL in this country. The programme focuses, among other aspects, in developing a rapid diagnostic test based on the patient’s anti-alpha-Gal response, and in identifying markers for disease exposure. We recently found evidence that treatment efficacy against Old World CL varies with parasite species, geographical locations and the development of secondary infections. This has implications on the treatment of this debilitating disease. The severity of a leishmaniasis ulcer partly depends on the patient’s previous exposure to sand fly bites. This explains the increased protection against CL in individuals living in CL-endemic areas and supports development of potential vaccine models based on sand fly salivary proteins. Furthermore, Old World CL patients produce high levels of anti-Gal antibodies (i.e. recognise terminal alpha-galactosyl epitopes). This discovery is currently being exploited for the making of rapid diagnostic tools and a potential protective glycovaccine model against CL. We hope that these tools can soon be applied in other CL-endemic countries, including refugee settings.